Advertisement

Advertisement

RNTX Stock Latest News

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

The FlyRein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside

PremiumRatings

Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside

20h ago

Rein Therapeutics doses first patient in Phase 2 trial of LTI-03

PremiumThe Fly

Rein Therapeutics doses first patient in Phase 2 trial of LTI-03

1M ago

Rein Therapeutics Completes Private Placement of Notes

PremiumCompany Announcements

Rein Therapeutics Completes Private Placement of Notes

1M ago

Rein Therapeutics Announces Immediate Board Director Resignation

PremiumCompany Announcements

Rein Therapeutics Announces Immediate Board Director Resignation

1M ago

Rein Therapeutics downgraded to Hold from Buy at Brookline

PremiumThe FlyRein Therapeutics downgraded to Hold from Buy at Brookline

2M ago

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

The Fly

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

2M ago

Rein Therapeutics Raises Capital via Private Note Offering

Company Announcements

Rein Therapeutics Raises Capital via Private Note Offering

3M ago

Rein Therapeutics Ends Key Financial Agreements

PremiumCompany Announcements

Rein Therapeutics Ends Key Financial Agreements

4M ago

Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth Potential

PremiumRatings

Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth Potential

5M ago

Rein Therapeutics Reports Q3 2025 Financial Results

PremiumCompany Announcements

Rein Therapeutics Reports Q3 2025 Financial Results

5M ago

Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments

PremiumRatings

Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments

5M ago

Rein Therapeutics announces publication on LTI-03

PremiumThe FlyRein Therapeutics announces publication on LTI-03

5M ago

Rein Therapeutics upgraded to Buy from Hold at Brookline

The Fly

Rein Therapeutics upgraded to Buy from Hold at Brookline

5M ago

Rein Therapeutics Resumes Phase 2 Trial for LTI-03

Company Announcements

Rein Therapeutics Resumes Phase 2 Trial for LTI-03

5M ago

Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03

PremiumThe Fly

Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03

5M ago

Rein Therapeutics Secures Third Pre-Paid Advance

PremiumCompany Announcements

Rein Therapeutics Secures Third Pre-Paid Advance

5M ago

Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03

PremiumThe Fly

Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03

6M ago

Rein Therapeutics initiated with a Buy at H.C. Wainwright

PremiumThe Fly

Rein Therapeutics initiated with a Buy at H.C. Wainwright

6M ago

Rein Therapeutics announces publication of data on LTI-03 in IPF

PremiumThe FlyRein Therapeutics announces publication of data on LTI-03 in IPF

7M ago

Rein Therapeutics Secures Second Advance in Funding Deal

Company Announcements

Rein Therapeutics Secures Second Advance in Funding Deal

7M ago

Rein Therapeutics files to sell 10M shares of common stock for holders

The Fly

Rein Therapeutics files to sell 10M shares of common stock for holders

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >